- Home
- GMM vs ZURA Comparison
GMM vs ZURA Comparison
Compare GMM & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- ZURA
- Stock Information
- Founded
- GMM 2017
- ZURA 2022
- Country
- GMM China
- ZURA United States
- Employees
- GMM N/A
- ZURA N/A
- Industry
- GMM
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GMM
- ZURA Health Care
- Exchange
- GMM Nasdaq
- ZURA Nasdaq
- Market Cap
- GMM 61.9M
- ZURA 69.9M
- IPO Year
- GMM 2023
- ZURA N/A
- Fundamental
- Price
- GMM $2.69
- ZURA $1.48
- Analyst Decision
- GMM
- ZURA Buy
- Analyst Count
- GMM 0
- ZURA 7
- Target Price
- GMM N/A
- ZURA $14.33
- AVG Volume (30 Days)
- GMM 22.6K
- ZURA 898.3K
- Earning Date
- GMM 08-15-2025
- ZURA 08-15-2025
- Dividend Yield
- GMM N/A
- ZURA N/A
- EPS Growth
- GMM 62.17
- ZURA N/A
- EPS
- GMM 6.37
- ZURA N/A
- Revenue
- GMM $41,360,953.00
- ZURA N/A
- Revenue This Year
- GMM N/A
- ZURA N/A
- Revenue Next Year
- GMM N/A
- ZURA N/A
- P/E Ratio
- GMM $0.41
- ZURA N/A
- Revenue Growth
- GMM 53.82
- ZURA N/A
- 52 Week Low
- GMM $1.69
- ZURA $0.97
- 52 Week High
- GMM $15.60
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- GMM 49.83
- ZURA 51.23
- Support Level
- GMM $2.52
- ZURA $1.44
- Resistance Level
- GMM $2.80
- ZURA $1.61
- Average True Range (ATR)
- GMM 0.23
- ZURA 0.13
- MACD
- GMM -0.01
- ZURA -0.03
- Stochastic Oscillator
- GMM 36.51
- ZURA 21.43
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.